These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12890531)

  • 1. Screening for inducers of kinase degradation.
    Neckers L
    Chem Biol; 2003 Jul; 10(7):587-9. PubMed ID: 12890531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicinal Chemistry - XXth International Symposium. Lead finding strategies and kinase selectivity.
    Rotella DP
    IDrugs; 2008 Nov; 11(11):774-8. PubMed ID: 18988116
    [No Abstract]   [Full Text] [Related]  

  • 3. Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR.
    Huezo H; Vilenchik M; Rosen N; Chiosis G
    Chem Biol; 2003 Jul; 10(7):629-34. PubMed ID: 12890536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.
    Traxler P; Furet P
    Pharmacol Ther; 1999; 82(2-3):195-206. PubMed ID: 10454197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
    Ghosh S; Liu XP; Zheng Y; Uckun FM
    Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-molecule kinase-inhibitor target assessment.
    Kung C; Shokat KM
    Chembiochem; 2005 Mar; 6(3):523-6. PubMed ID: 15696508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor dependence in human tumors: more than just expression?
    Arteaga CL
    Oncologist; 2002; 7 Suppl 4():31-9. PubMed ID: 12202786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
    J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput biochemical kinase selectivity assays: panel development and screening applications.
    Card A; Caldwell C; Min H; Lokchander B; Hualin Xi ; Sciabola S; Kamath AV; Clugston SL; Tschantz WR; Leyu Wang ; Moshinsky DJ
    J Biomol Screen; 2009 Jan; 14(1):31-42. PubMed ID: 19073965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperosmotic stress induces phosphorylation of cytosolic phospholipase A(2) in HaCaT cells by an epidermal growth factor receptor-mediated process.
    Rodríguez I; Kaszkin M; Holloschi A; Kabsch K; Marqués MM; Mao X; Alonso A
    Cell Signal; 2002 Oct; 14(10):839-48. PubMed ID: 12135705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen.
    Almholt DL; Loechel F; Nielsen SJ; Krog-Jensen C; Terry R; Bjørn SP; Pedersen HC; Praestegaard M; Møller S; Heide M; Pagliaro L; Mason AJ; Butcher S; Dahl SW
    Assay Drug Dev Technol; 2004 Feb; 2(1):7-20. PubMed ID: 15090206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing the kinase field: new targets and second generation inhibitors.
    Laufer S; Bajorath J
    J Med Chem; 2015 Jan; 58(1):1. PubMed ID: 25490234
    [No Abstract]   [Full Text] [Related]  

  • 14. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of EGFR signal-transduction modulation by tyrosine kinase inhibitors to chemosensitivity and programmed cell death in lung cancer cell lines.
    Lei W; Koty PP; Levitt ML
    Methods Mol Med; 2003; 74():127-43. PubMed ID: 12415691
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid screening of drug candidates against EGFR/HER2 signaling pathway using fluorescence assay.
    Khanjani F; Sajedi RH; Hasannia S
    Anal Bioanal Chem; 2018 Dec; 410(30):7827-7835. PubMed ID: 30338368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
    Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
    Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting ErbB receptors in high-grade glioma.
    Berezowska S; Schlegel J
    Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
    Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
    Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.